Figure 8.

Gene‐edited GMEC inhibits PANoptosis activation by high expression of LYZ. a) Primary GMEC and gene‐edited GMEC were treated with 5 µg mL⁻¹ LPS and 10 µg mL⁻¹ LPS for 12 h, and then the culture medium was replaced for 12 h to detect the protein expression levels of GSDMD, NLRP3, Caspase 1, Cle‐Caspase 1, ASC, Caspase 8, Cle‐Caspase 8, Bcl2, Caspase 3, p‐RIPK3, t‐RIPK3, p‐MLKL and t‐MLKL. b) The protein expression of NLRP3 in GMEC was detected by IF. Scale bar: 50 µm. c) The protein expression of NLRP3 in GMEC organoids was detected by IF. Scale bar: 100 µm. d) Primary GMEC and gene‐edited GMEC were treated with 5 µg mL⁻¹ LPS and 10 µg mL⁻¹ LPS for 12 h, and then the culture medium was replaced for 12 h to detect the proportion of apoptosis and necrosis (n = 3 per group). Scale bar: 100 µm. e) Primary GMEC and gene‐edited GMEC were treated with 5 µg mL⁻¹ LPS and 10 µg mL⁻¹ LPS for 12 h, and then the culture medium was replaced for 12 h to detect apoptosis ratio (n = 3 per group). f) Under inflammatory conditions, primary GMEC were treated with Z‐VED, MCC950 and Nec‐1 inhibitors to inhibit the activation of PANoptosis and to detect the protein expression of ZO‐1 and Occludin.